Home・Lista de Ações・Glaukos Corp

Glaukos Corp

Fechado

SetorSaúde

171.94 -0.78

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

166.51

Máximo

173.49

Indicadores-chave
By Trading Economics
Rendimento	114M -20M
Vendas	7.5M 151M
EPS	-0.18
Margem de lucro	-13.139
Funcionários	1,094
EBITDA	124M -5.3M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+11.51% upside

Dividendos
By Acuity
Próximos Ganhos	28 de out. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.8B 8.9B
Abertura anterior	172.72
Fecho anterior	171.94

Sentimento de Notícias

By Acuity

50%

151 / 340 Ranking em Healthcare

Glaukos Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 de jul. de 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 de jul. de 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 de jul. de 2026, 21:22 UTC

Social Media

News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 de jul. de 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 de jul. de 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 de jul. de 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 de jul. de 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Comparação entre Pares

Variação de preço

Glaukos Corp Previsão

Preço-alvo

By TipRanks

11.51% parte superior

Previsão para 12 meses

Média 185.91 USD 11.51%

Máximo 215 USD

Mínimo 153 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Glaukos Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Glaukos Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

151 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.